Hot topics | Coronavirus pandemic

Palatin to present Peptides Platform at the TIDES USA Conference

Palatin to present Peptides Platform at the TIDES USA Conference

The conference, which will take place on September 20-23 in Boston, Massachusetts, today announced a speaker and two poster presentations at the upcoming TIDES USA hybrid conference.

Among the many advantages of melanocortins, the gut and the eye provide a wide range of opportunities to promote the treatment of inflammation.

Dr. Spana is a guest speaker, and will discuss the company's broad expertise in melanocortin peptides, including its development programs for inflammation. The poster presentations of John Dodd, Ph.D., Senior Vice President of Preclinical Research, show the potential use of melanocortins in inflammation. The paper presents animal disease models based on colon inflammation

TIDES USA is presenting multiple drug development functional groups from development through commercialization for oligos, peptides and mRNA, and genome editing products.

The details of the presentation and the poster are:

  • Dr. Spana's presentation, "The Development of Melanocortin-based Peptide Therapeutics: Vyleesi (FDA approved) and Next Generation of Novel Pepticides that Resolv
  • Two poster presentations by Dr. Dodd provide an overview of the potential effect of agonists on inflammatory diseases. The second poster shows an entrant model of an inflammatory disease. The posters are titled: At the end of the year.
    • Probating the Role of Melanocortin Receptor Agonists in Experimental Immune-Mediated Diseases.
    • On the Colitis in Rats and the Toxicologic Assessment of PL8177 in Beagle Dogs, londons: effects of the Melanocortin Receptor Agonist LP

Both posters will be available on the TIDES USA conference website for registered attendees and available today on Palatin's website at

About Melanocortins and Inflammation of Inflamation and MelonocORtines and inflammations

The melanocortin receptor system has an effect on the food intake, metabolism, sexual function, inflammation, and immune responses. Five melanocortin receptors are MC1r and CM5r. In addition to the use of receptor-specific antagonists, which activate receptor function, the modification of these receptors can have significant pharmacological effects.

We can activate natural pathways to resolve a disease inflammation. Many tissues and immune cells that live in the eye express melanocortin receptors, enabling us to directly activate the natural pathway to resolve inflammation of diseases

About Palatin

Palatin is a biopharmaceutical company that develops first-class medicines that can be controlled by natriuretic peptides, with targeted, receptor-specific product candidates for the treatment of diseases with significant Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For more information about Palatin, please visit Pa Latin's website at

Statements with forward-looking results are forward.

"forward-looking statements" in the Securities Litigation Reform Act of 1995, except statements in this press release that are not historical facts, including statements about future expectations of Palatin, such as statements on clinical trial plans and potential results for Palatin intends to make such forward-looking statements subject to the safe harbor created by Pa Latin. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could make Palatin's actual results materially different from its historical results or from any results expressed or implied by such forward forward looking statement. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory action by the FDA and other regulatory and and the need for regulatory approvals Palatin is not responsible for releasing press releases that aren't updated for events that occur after the date of this press release.

SOURCE Palatin Technologies Inc.

Related Links

You may also like: